Lung cancer

Dr. Raghu Nandan Joins Los Angeles Cancer Network

Retrieved on: 
Thursday, December 1, 2022
University of California, Irvine, Multimedia, Long Beach Memorial Medical Center, Patient, MD, Suite, Madras Medical College, Faculty, Lung cancer, Internal medicine, SUNY Downstate Medical Center, UC, Medical device

LAKEWOOD, Calif., Dec. 1, 2022 /PRNewswire/ -- Los Angeles Cancer Network (LACN), one of the leading cancer and blood disorder centers in Los Angeles, is proud to announce that board-certified hematologist/oncologist Raghu Nandan, MD and his team have officially joined it's growing network.

Key Points: 
  • LAKEWOOD, Calif., Dec. 1, 2022 /PRNewswire/ -- Los Angeles Cancer Network (LACN), one of the leading cancer and blood disorder centers in Los Angeles, is proud to announce that board-certified hematologist/oncologist Raghu Nandan, MD and his team have officially joined it's growing network.
  • "We are proud to welcome Dr. Nandan to LACN," said Troy Simon, LACN's CEO.
  • Dr. Raghu Nandan completed his medical education at Madras Medical College in India in 1984.
  • About Los Angeles Cancer Network:
    The mission of The Los Angeles Cancer Network is to provide unparalleled care to each patient that comes through our doors.

Insights on the Interventional Oncology Global Market to 2028 - More Efficiency and Quick Recovery Offered by Interventional Oncology is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Health, Oncology, Neoplasm, Patient, Liver cancer, Diagnosis, Otorhinolaryngology, PET, Product type, Radiation therapy, Disorder, Risk, Lung cancer, Cancer, Radiation, Medical-surgical nursing, Malignant Tumour, Breast cancer, Health, Radiology, Kidney cancer, Prostate cancer, Lymph, Infection, Safety, Medical imaging, IO

The Global Interventional Oncology Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 6.2% CAGR during the forecast period.

Key Points: 
  • The Global Interventional Oncology Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 6.2% CAGR during the forecast period.
  • Interventional oncology (IO) is an emerging subspecialty that emphasizes on using image-guided processes (diagnostics/surgeries) to improve cancer therapy.
  • Along with surgery, medication, and radiation, IO is currently the fourth pillar of modern oncology care.
  • Because of the rising number of cancer cases among individuals around the world, the interventional oncology market is expected to rise faster in the coming years.

The Worldwide Peptide Therapeutics Industry is Expected to Reach $58.4 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Health, Biotechnology, Population growth, Innovation, Lysine, Colon, Peptide, Administration, Liraglutide, CVD, Prevalence, Serum, Blood, Disorder, Hormone, Brain, Instability, Neuropeptide, Route of administration, Ageing, Protein, Pancreas, Inflammation, Medicine, Death, Disease, Half-life, Carbon, Hypercholesterolemia, DPP, Lung cancer, Growth hormone, Cardiovascular disease, Cancer, Absorption, Risk, Therapy, Lanreotide, Hyperglycemia, Water, Application, Organic acid, Breast cancer, Somatostatin, Plasma, Breast, Obesity, Fine chemical, Vaccine

The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Key Points: 
  • The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
  • Peptide therapeutics are polypeptides or peptides (oligomers or short polymers of amino acids) that are utilized to treat disorders.
  • Peptide treatments replicate natural peptide functions such as hormones, neurotransmitters, growth factors, ion channel ligands, and anti-infectives.
  • Liraglutide, the most popular diabetic medicine on the market, contains a lipid chain that increases plasma circulation and provides long-term absorption.

ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards

Retrieved on: 
Thursday, December 1, 2022
ALK, Life expectancy, Human, Doctor of Philosophy, Helpline, EML4-ALK positive lung cancer, Clinical trial, Conference, Smoker, Cancer, Multimedia, Large-cell lung carcinoma, Partnership, Caregiver, Patient, Anaplastic lymphoma kinase, Charity Navigator, Health equity, Disease, MD, Lung cancer, Public policy, Research, BUT, Quality of life, MPH, Survival, Strathcona County, FDA, Pharmaceutical industry, Medical imaging

WASHINGTON, Dec. 1, 2022 /PRNewswire/ -- Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards. The grant monies, totaling $1.75 million, were raised by ALK Positive and represent patients with ALK-positive non-small cell lung cancer themselves directly influencing the direction and focus of the research that affects their lives. This year's awardees are the third cohort to receive these awards.

Key Points: 
  • To transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program
    WASHINGTON, Dec. 1, 2022 /PRNewswire/ -- Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards.
  • The recipients of the 2022 ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards are:
    "We are thrilled to continue our partnership with ALK Positive through these impactful research awards," said Upal Basu-Roy, PhD, MPH, executive director of research at LUNGevity Foundation.
  • The three scientists selected for the 2022 ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards are international experts in the field.
  • ALK Positive has implemented multiple programs to improve care for ALK- positive cancer patients, and accelerate the development and availability of improved treatments.

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

Retrieved on: 
Thursday, December 1, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, AstraZeneca, Natural killer T cell, Adenosine, Euronext Paris, Immune system, Pharmacokinetics, Antibody, Sanofi, Cancer, Novo Nordisk, Clinic, CD39, Partnership, Patient, Tumor microenvironment, Oncology, UNIL, Trastuzumab, Department of Oncology, University of Cambridge, IPHA, ESMO, Lung cancer, Neoplasm, IPC, ATP, IPH, Bristol Myers Squibb, Congress, Durvalumab, Immunity, European Society for Medical Oncology, Safety, Vaccine, Pharmaceutical industry, MD, Intrinsic and extrinsic properties

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.
  • IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment.
  • By targeting the adenosine immunosuppressive pathway, IPH5301 has the potential to promote anti-tumor immune responses across a wide range of tumors.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

University of North Carolina's Tylee Craft Selected for 2022 Disney Spirit Award

Retrieved on: 
Wednesday, November 30, 2022
UNC, University of North Carolina, University, Tar Heel, Patient, UNC Lineberger Comprehensive Cancer Center, Courage, Walt Disney World, Disney Sports Enterprises, Disney's Wide World of Sports Spirit Award, Disease, Lung cancer, ESPN College Basketball, White ribbon, Cancer, Family, Boston College, University of North Carolina at Chapel Hill, Immunotherapy, Film, Craft

LAKE BUENA VISTA, Fla., Nov. 30, 2022 /PRNewswire/ -- University of North Carolina wide receiver Tylee Craft has been named the recipient of the 2022 Disney Spirit Award just eight months after nearly losing his life to lung cancer.

Key Points: 
  • LAKE BUENA VISTA, Fla., Nov. 30, 2022 /PRNewswire/ -- University of North Carolina wide receiver Tylee Craft has been named the recipient of the 2022 Disney Spirit Award just eight months after nearly losing his life to lung cancer.
  • "The Disney Spirit Award honors people like Tylee who focus on helping others even while facing their own tremendous adversity."
  • Kelley will present Craft with the Disney Spirit Award during the Home Depot College Football Awards December 8, 2022.
  • Craft is the 27th recipient of the Disney Spirit Award and the first from the University of North Carolina.

New Study to Address Cancer Treatment Resistance for People Who Are KRAS Positive

Retrieved on: 
Wednesday, November 30, 2022
Doctor of Philosophy, Patient, SAN, Drug resistance, Prevalence, Gene, Cancer, Harvard Medical School, Multimedia, Risk, KRAS, Large-cell lung carcinoma, Partnership, SPARK, RAS, Dana–Farber Cancer Institute, Lung cancer, George M. Low Center for Industrial Innovation, Travel, Survivor, Medicine, Drug development, MD, Colorectal cancer, Research, Addario Lung Cancer Medical Institute, Alchemy, Hope, Liquid biopsy, Survival, Foundation Medicine, FDA, Pharmaceutical industry, Medical imaging, Medical device

"The development of treatment resistance is unfortunately common in patients with lung cancers and other tumor types with the KRAS G12C mutation," said Dr. Awad.

Key Points: 
  • "The development of treatment resistance is unfortunately common in patients with lung cancers and other tumor types with the KRAS G12C mutation," said Dr. Awad.
  • "Treatment resistance is a harsh reality for too many people with lung cancer," said Richard Erwin, executive director of clinical operations at ALCMI.
  • SPARK Study blood samples will be analyzed to help advance research and treatment for KRAS-positive lung cancer.
  • "The SPARK study will research why KRAS-mutant cancers develop drug resistance, which will then fuel research into preventing and overcoming resistance.

Hoag is the First Hospital in Orange County to Perform Breakthrough Treatment Option for Patients with Severe COPD/Emphysema

Retrieved on: 
Tuesday, November 29, 2022
Hoag, U.S. News & World Report, Heart, Diagnosis, Elective surgery, Neuroscience, Lung, OC, Pulmonology, Multimedia, COPD, Life, Respiratory disease, Physician, Patient, Nursing, Interstitial lung disease, Disease, Pulmonary hypertension, Lung cancer, Sleep, Asthma, Cancer, Health, Asa, Walking, Atmosphere, Quality of life, Urinary tract infection, News, American Nurses Credentialing Center, ANCC, Pressure, Diaphragm, Health insurance, Medical imaging, Hospital, Goodman

NEWPORT BEACH, Calif., Nov. 29, 2022 /PRNewswire/ -- Hoag is the first hospital in Orange County to perform a new lung valve treatment on a patient with severe COPD (chronic pulmonary obstructive disease) and emphysema. The procedure has the potential to benefit a number of patients in Orange County who suffer from major quality of life issues related to shortness of breath.

Key Points: 
  • NEWPORT BEACH, Calif., Nov. 29, 2022 /PRNewswire/ -- Hoag is the first hospital in Orange County to perform a new lung valve treatment on a patient with severe COPD (chronic pulmonary obstructive disease) and emphysema.
  • The procedure has the potential to benefit a number of patients in Orange County who suffer from major quality of life issues related to shortness of breath.
  • "We are thrilled to bring this minimally invasive option to patients in Orange County," said Javier Longoria, M.D., the only fellowship-trained interventional pulmonologist in Orange County, who performed the first procedure earlier this month.
  • "Finally having a breakthrough treatment option to help patients with this disease get back to their best self is very exciting," said Dr. Longoria.

Interventional Oncology Market - Global Forecast to 2026 - Expansion in the Emerging Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 29, 2022
Health, Oncology, Incidence, Liver cancer, Radiofrequency ablation, Brain, Prevalence, Geography, Hospital, ASC, TACE, Asia-Pacific Telecommunity band plan in the 700 MHz band, Kidney cancer, Lung cancer, Cancer, Electroporation, SIRT, Therapy, Prostate cancer, TAE, Medicine, Medical imaging, Cryoablation

The "Interventional Oncology Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interventional Oncology Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The interventional oncology global market is expected to grow at a high single from 2022 to 2029.
  • Factors such as technological advancements in the field of interventional oncology and expansion in emerging markets are opportunities for the market.
  • Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others.

Petfood Consumer Rights Council Launches, Announces Founding Member Drive

Retrieved on: 
Tuesday, November 29, 2022
Degenerative disease, SALT, History, Organization, PETS, Tobacco, Dog, Arthritis, Obesity, Diabetes, PCRC, Lung cancer, Cat, Cancer, Health, Research, Science, Animal, Smoking, Pet

SALT LAKE CITY, Nov. 29, 2022 /PRNewswire/ -- The Petfood Consumer Rights Council , a first-of-its-kind consumer protection and animal welfare organization, has launched and announced its first key initiative, a 90-day founding member drive.

Key Points: 
  • SALT LAKE CITY, Nov. 29, 2022 /PRNewswire/ -- The Petfood Consumer Rights Council , a first-of-its-kind consumer protection and animal welfare organization, has launched and announced its first key initiative, a 90-day founding member drive.
  • The PCRC is the first 501(c)(3) not-for-profit organization in history devoted exclusively to advancing the rights and interests of American pet owners.
  • "I'm delighted to announce that this revolutionary organization is finally ready to begin its work," says Daniel Schulof, the PCRC's founder.
  • And our voting members will be the ones choosing our leadership and setting our agenda each year, not some deep-pocketed corporate benefactor.